ValuEngine Downgrades Infinity Pharmaceuticals (INFI) to Strong Sell
Infinity Pharmaceuticals (NASDAQ:INFI) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
A number of other equities analysts have also issued reports on the stock. Wells Fargo & Company upgraded shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th.
Infinity Pharmaceuticals (NASDAQ INFI) traded down $0.02 during mid-day trading on Friday, hitting $1.91. 600,197 shares of the company were exchanged, compared to its average volume of 1,081,085. Infinity Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $3.84.
In related news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The stock was purchased at an average price of $1.26 per share, for a total transaction of $2,016,057.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.81% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new position in Infinity Pharmaceuticals in the 1st quarter valued at about $1,588,000. FMR LLC bought a new position in Infinity Pharmaceuticals in the 2nd quarter valued at about $349,000. Goldman Sachs Group Inc. grew its position in Infinity Pharmaceuticals by 75.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 246,234 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 105,497 shares in the last quarter. Vanguard Group Inc. grew its position in Infinity Pharmaceuticals by 27.7% in the 1st quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after buying an additional 1,021,128 shares in the last quarter. Finally, Zacks Investment Management bought a new position in Infinity Pharmaceuticals in the 2nd quarter valued at about $101,000. Hedge funds and other institutional investors own 54.41% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.